Skip to content

What Is Talon Therapeutics Presenting at The 2012 ASH Meeting ?

December 12, 2012

      Talon Therapeutics is presenting the following Abstracts for orphan drug Marqibo (vinCRIStine sulfate LIPOSOME injection) for the treatment of Acute Lymphoblastic Leukemia (ALL), at the 2012 Annual American Society of Hematology (ASH) Meeting, in Atlanta, Georgia, December 8 – 11, 2012 : 

  1. ASH Abstract # 1497 : Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer
  2.  ASH Abstract # 3568 : Neurotoxicity Profile of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Monotherapy in Adults with Relapsed Acute Lymphoblastic Leukemia and Universal Prior Standard Vincristine Exposure  
  3. ASH Abstract # 2457 : Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Facilitates Increased Delivery of Vincristine Sulfate to Target Cancer Tissues.  

       Facts about Mariqibo

  1. FDA Orphan Drug Designation (ODD) January 8, 2007 for ALL
  2. Receives FDA Accelerated Approval on August 9, 2012 for ALL   
  3. Receives European Medicines Agency (EMA) Orphan Drug Designation on July 8, 2008
  4. Submission of a Marketing Authorization Application to EMA in 2013. 

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: